Sugi Predict

Sugi Predict / Compounds / SCHEMBL21604553

SCHEMBL21604553

SCHEMBL21604553

Cc1nc2cc(Br)c(F)cc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.59
▸ NPC1 O15118 2/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ PKM P14618 2/20 0.59
▸ TP53 P04637 1/20 0.59
▸ MAPT P10636 1/20 0.59
▸ HPGD P15428 1/20 0.59
▸ GAA P10253 1/20 0.55
▸ ILK Q13418 1/20 0.46
▸ ALOX15 P16050 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CHRNB2 P17787 1/20 0.41
▸ CHRNA4 P43681 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25804821 0.93 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL30521646 0.93 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL14297419 0.84 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL21606916 0.81 GAA (0.70) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL3660199 0.79 ILK (0.40) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL25424052 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL21882016 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL19709633 0.78 ILK (0.40) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL20049285 0.78 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL360218 0.78 AXL (0.53) SMN1; SMN2NPC1RAB9AHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419551-A1 O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY Eli Lilly and Company (US) 2024-08-28 — — EP disclosed
CN-112955446-B 6-Fluoro-2-methylbenzo [ D ] thiazol-5-yl compounds 伊莱利利公司 2024-07-12 — — CN disclosed
CN-118139880-A O-linked N-acetylglucosamine hydrolase (OGA) inhibitor combination therapy 伊莱利利公司 2024-06-04 — — CN disclosed
WO-2023070064-A1 O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY ELI LILLY AND COMPANY (US) 2023-04-27 — — WO disclosed
WO-2023070064-A1 O-GLCNACASE (OGA) INHIBITOR COMBINATION THERAPY ELI LILLY AND COMPANY (US) 2023-04-27 — — WO disclosed
EP-3856739-A1 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS Eli Lilly and Company (US) 2021-08-04 — — EP disclosed
CN-112955446-A 6-fluoro-2-methylbenzo [ D ] thiazol-5-yl compounds 伊莱利利公司 2021-06-11 — — CN disclosed
US-20210122763-A1 OGA INHIBITOR COMPOUNDS JANSSEN-CILAG S.A. (ES) 2021-04-29 — — US disclosed
US-20210115040-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-04-22 — — US disclosed
US-10836773-B1 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds ELI LILLY AND COMPANY (US) 2020-11-17 — — US disclosed
US-10836773-B1 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds ELI LILLY AND COMPANY (US) 2020-11-17 — — US disclosed
US-20200354370-A1 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds ELI LILLY AND COMPANY 2020-11-12 — — US disclosed
US-20200354370-A1 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds ELI LILLY AND COMPANY 2020-11-12 — — US disclosed
US-10752632-B2 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds ELI LILLY AND COMPANY (US) 2020-08-25 — — US disclosed
US-10752632-B2 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds ELI LILLY AND COMPANY (US) 2020-08-25 — — US disclosed
WO-2020068530-A1 6-FLUORO-2-METHYLBENZO[D]THIAZOL-5-YL COMPOUNDS ELI LILLY AND COMPANY (US) 2020-04-02 — — WO disclosed
US-20200095254-A1 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds ELI LILLY AND COMPANY 2020-03-26 — — US disclosed
WO-2019243528-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 — — WO disclosed
WO-2019243530-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10752632-B2 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds MAPT, HTT, TFEB SMN1; SMN2 198/4885NPC1 80/4885RAB9A 218/4885
US-20210122763-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN SMN1; SMN2 103/4885NPC1 1281/4885RAB9A 2809/4885
US-20200095254-A1 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds MAPT, HTT, PSEN2 SMN1; SMN2 90/4885NPC1 69/4885RAB9A 273/4885
US-20210115040-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN SMN1; SMN2 103/4885NPC1 1281/4885RAB9A 2809/4885
US-20200354370-A1 6-Fluoro-2-Methylbenzo[d]thiazol-5-yl Compounds MAPT, HTT, PSEN2 SMN1; SMN2 90/4885NPC1 69/4885RAB9A 273/4885
US-10836773-B1 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds MAPT, HTT, PSEN2 SMN1; SMN2 90/4885NPC1 69/4885RAB9A 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.